Rutinib Tablet 10 mg contains Ruxolitinib, an oral Janus kinase (JAK) inhibitor used in the treatment of myeloproliferative disorders and certain inflammatory conditions. Ruxolitinib works by modulating the JAK-STAT signaling pathway, which is involved in the regulation of immune function, blood cell production, and inflammation.

Rutinib is commonly prescribed for conditions such as intermediate or high-risk myelofibrosis, polycythemia vera, and other disorders characterized by abnormal blood cell proliferation or immune dysregulation. By targeting the underlying molecular pathways, Ruxolitinib helps control symptoms, reduce organ enlargement, and improve quality of life.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Ruxolitinib 10 mg per tablet

Mechanism of Action

Ruxolitinib selectively inhibits Janus kinase (JAK) 1 and JAK2, key enzymes in the JAK-STAT signaling pathway. This inhibition:

• Reduces abnormal signaling that leads to excessive blood cell production

• Decreases inflammation and cytokine-mediated symptoms

• Helps control splenomegaly (enlarged spleen) in myelofibrosis

• Modulates immune activity in certain inflammatory disorders

By targeting these pathways, Rutinib provides symptom relief, improves hematologic parameters, and slows disease progression in treated patients.

Indications

Rutinib Tablet 10 mg is indicated for:

• Intermediate or high-risk myelofibrosis

• Polycythemia vera in patients resistant or intolerant to hydroxyurea

• Certain other myeloproliferative disorders as determined by a healthcare provider

• Off-label use for selected inflammatory conditions under specialist supervision

It is intended for adult patients and should be prescribed by physicians experienced in the management of hematologic or immune-mediated disorders.

Dosage and Administration

The typical dose of Rutinib is 10 mg orally twice daily, or as prescribed by a physician based on patient condition, response, and tolerability. Tablets should be swallowed whole with water and can be taken with or without food.

Regular monitoring of blood counts, liver function, and renal function is essential during treatment, as dose adjustments may be required to manage side effects. Gradual tapering may be needed when discontinuing therapy to avoid rebound symptoms.

Benefits

• Controls abnormal blood cell production

• Reduces spleen size and associated discomfort

• Alleviates fatigue, night sweats, and other disease-related symptoms

• Improves quality of life in patients with myeloproliferative disorders

• Convenient oral dosing for long-term management

Precautions

• Use caution in patients with a history of infections, liver or kidney impairment, or low blood counts

• Patients should avoid live vaccines during treatment

• Inform your doctor about all medications to prevent interactions, especially with other immunosuppressive agents

• Not recommended during pregnancy or breastfeeding

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Headache and dizziness

• Fatigue and weakness

• Nausea or diarrhea

• Increased susceptibility to infections

• Anemia or thrombocytopenia

Serious but rare side effects include severe infections, bleeding, liver toxicity, and low blood cell counts. Prompt medical attention is necessary if these occur.

Storage

Store below 30°C in a dry place, protected from light. Keep out of reach of children.

Rutinib Tablet 10 mg offers targeted therapy for myeloproliferative disorders, controlling abnormal blood cell production, reducing organ enlargement, and improving patient quality of life under specialist supervision.